Half-year report · Q2
177A.TEDINET S100UQDH
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks11 of 11 passed
Key figures · 29
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥4.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Operating income | ¥380m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥417m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥636m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥367m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥277m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥385m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥277m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥8.5bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥6.6bn | at 2024-03-31 | Cons. | Assets |
| Total liabilities | ¥3.2bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥3.2bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥5.3bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥3.3bn | at 2024-03-31 | Cons. | Net assets |
| Cash and deposits | ¥3.3bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.7bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥3.3bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.7bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥518m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥824m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥467m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥577m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥1.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥55.7 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.43 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 62.0% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.7% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 13
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥265m |
| jpcrp040300-q2r_E38689-000Cell Process Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥630m |
| jpcrp040300-q2r_E38689-000Cell Process Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥630m |
| jpcrp040300-q2r_E38689-000Cell Process Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥191m |
| jpcrp040300-q2r_E38689-000Microbiological Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥777m |
| jpcrp040300-q2r_E38689-000Microbiological Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥777m |
| jpcrp040300-q2r_E38689-000Microbiological Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥104m |
| jpcrp040300-q2r_E38689-000Tissue Culture Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E38689-000Tissue Culture Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E38689-000Tissue Culture Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥350m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥2.5bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥2.5bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥645m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 351
| Item | Context | Value | Unit |
|---|---|---|---|
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 11 of 11 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |